Led by GHSU Cancer Center Director Samir N.

Both have been safely used by itself or in conjunction with other cancer therapies, but hardly ever for prostate cancers. Preclinical animal research in Khleif's lab found that the mix of Provenge with these two other drugs resulted in a significant increase in survival and complete tumor regression in more than 50 % of mice. Predicated on these total results, Dendreon Corporation, the manufacturers of Provenge, and Khleif are collaborating upon this first in human being trial. Khleif joined the GHSU Cancer Middle as its Director after more than 22 years in the Tumor Vaccine Section at the National Malignancy Institute. His lab targets research into vaccines to help the disease fighting capability eradicate and target cancers. Prostate cancer may be the most common cancer and the next leading reason behind cancer deaths among men generally in most Western countries..Since bleeding in the mind after damage can be a common and critical problem for patients, additional research into this region can lead to effective therapies for accelerated human brain recovery after injury. .. Better stroke treatment could save a large number of lives every year An eight-month research at 21 Canadian hospitals, led by a Canadian Stroke Network and Cardiovascular and Stroke Basis researcher, found that nearly all patients didn’t receive treatment on an severe stroke unit. Moira Kapral, lead writer of the analysis to be released in the July problem of the journal Stroke. Dr. Kapral utilized data gathered through the Registry of the Canadian Stroke Network and examined stroke treatment in eight provinces.